Tesofensine vs Tirzepatide
Side-by-side comparison of Tesofensine and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Tesofensine
Tirzepatide
Tesofensine
Tesofensine (NS2330) is an orally-administered small-molecule triple monoamine reuptake inhibitor — it blocks the reuptake of noradrenaline, dopamine, and serotonin, placing it in the same broad pharmacologic class as…
Lowest listed price: $79.99 across 2 listings
Full Tesofensine profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | Tesofensine | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Metabolic & Weight Loss |
| Research Stage | Preclinical | FDA Approved |
| Mechanism of Action | Tesofensine blocks the presynaptic reuptake of three monoamine neurotransmitters: noradrenaline (norepinephrine), dopamine, and serotonin. By inhibiting the neurotransmitter transporters (NET, DAT, and SERT respectively), tesofensine raises synaptic… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | — | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 0.25 mg - 1 mg daily (oral) | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | — | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | Tesofensine's side effect profile reflects its monoamine-enhancing mechanism. Most effects are predictable extensions of NE, DA, and 5-HT elevation. The cardiovascular profile is the dominant clinical concern and the primary reason regulators have not approved… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 298.24 g/mol | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price tracking
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Tesofensine: potential benefits
- Significant weight loss (10-15% body weight)
- Appetite suppression
- Increased metabolic rate
- Enhanced dopamine-driven motivation
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between Tesofensine and Tirzepatide?
Tesofensine is a weight loss that tesofensine blocks the presynaptic reuptake of three monoamine neurotransmitters: noradrenaline (norepinephrine), dopamine, and serotonin. by inhibiting the neurotransmitter…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (not reported vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Tesofensine or Tirzepatide?
Tesofensine has a half-life of not reported. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Tesofensine or Tirzepatide?
Lowest listed price on BodyHackGuide: Tesofensine from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Tesofensine and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Tesofensine and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Tesofensine or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.